Anti-PD-1 therapeutic antibodies function through binding to PD-1 on tumour-reactive T cells and inhibiting the PD-1:PD-L1 interaction, thereby reinvigourating the anti-tumour T-cell response4, 5, 6. This evidence concerns the gene PDCD1 and neoplasm.